The International Contrast Media Market is expected to grow at a CAGR of 6.3 % during forecast period of 2017-2023. The Worldwide Contrast Media Industry is going to continue with the same trends of growth during the forecast period.

The Contrast Media Market appears to be fiercely competitive & fragmented owing to the presence of numerous matured & small key players accounting for a substantial market share. These market players try to gain competitive advantage through strategic partnership, acquisition, expansion, collaboration, product & technology launch. They invest heavily in the R&D to develop a technology that is completely on a different level compared to their competition.

Contrast media are substances which are utilized to improve the contrast of fluids in the body during medical imaging. It is basically used to enhance the visibility of blood vessels and GI tract. The global contrast media market is growing with the steady pace; mainly due to the increasing prevalence of different diseases such as GIT diseases and cardiac diseases.

The major factors influencing the growth of the market include increasing technology advancement in contrast medium, increasing prevalence of cancer and cardiac diseases, growth in emerging markets for imaging technology, increasing demand for diagnostics, and image guide procedures and various others.

GE Healthcare an American multinational company headquartered in the U.S., is one of the leading players in the contrast medium market with manufacturing and distribution of diagnostic imaging agents with more than 100 countries. OMNISCAN and VISIPAQUE are the major products of the company. Recently in March 2017, the company showcased its MRI contrast media product range at the European Congress of Radiology (ECR) 2017 meeting by launching Clariscan, which is a macrocyclic agent and is a gadolinium-based contrast agent (GBCA). Clariscan is intended to support effective visualisation of abnormalities in the brain, spine, and associated tissues. The launch of this product will be provided alongside GE Healthcare’s comprehensive support services and solutions to healthcare physicians across the globe. The demand for contrast media has altogether expanded over the previous decade because of increasing advancement in procedures in MR imaging, raising the significance of uninterrupted and sustainable product supply, and in addition meeting the individual needs of patients undergoing diagnostic techniques. Knowing the demand for contrast medium, GE healthcare invested over USD 65 million in its overall supply across the globe from 2013 and 2016, to increase its manufacturing capacity. GE contrast media products are utilized as a part of more than 70 million systems for every year, identical to infusion in two patients for each second. In 2015, 62 million patients diagnosed using GE contrast media and acquired major share for the global contrast media market.

Global Contrast Media Market Segmentation:

Global contrast media market is segmented on the basis of type into intravenous contrast materials, iodine-based and other. On the basis of procedures they are segmented into X-ray, computed tomography, magnetic resonance imaging, ultrasound and other. On the basis of application they are cardiovascular disorders, oncology, nephrological disorders and by route of administration they are rectal, oral, injectable and other.

International Contrast Media Market Regional Analysis:

On regional basis, contrast media market is dominated by North America which is followed by Europe. Presence of major players in North America and Europe and increasing prevalence of GI disease are the major factor for the growth of the market in this region. Asia Pacific is the third largest market and the fastest growing contrast media market. Rising awareness regarding product benefits among consumers and a huge population base in this region is the major factor for the growth of the market.

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Event Details

PULSUS group cordially welcomes researchers, academicians, students and business professionals in the field of Cancer Science and Therapy from around

more

Event Details

PULSUS group cordially welcomes researchers, academicians, students and business professionals in the field of Cancer Science and Therapy from around the world to participate in the upcoming “2nd World Congress on Advanced Cancer Science & Therapy” to be held at Dubai, UAE during January 28-29, 2019. The meeting for this year will revolve around the theme “An Assembly of Curious Facts and Cure for Cancer” thus relaying the most cutting-edge findings in this field.

The two-day meeting is going to be an event to look forward for its enlightening symposiums & workshops from established experts in cancer therapy, potential keynote talks from eminent speakers, informative oral sessions and innovative poster presentations.

Cancer Therapy 2019 is an extraordinary event that invites participants from different leading universities, clinical research institutions and various diagnostic companies to share their research experiences in all aspects of this rapidly expanding field and provides an opportunity to meet and communicate with leading doctors, surgeons, scientists, academic professionals from around the world and listen to top speakers on new developments that impact and advance future of cancer science. It serves as a global platform to know about the current developments and new approaches in the field of cancer science and therapy. It will also prove to be a brilliant open door for businesses keen on expanding their global market reach. This event is an effort to understand the underlying new techniques which are amended to increase effectiveness, accuracy, sustainability, and quality of life.